コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ad repeat hormone measures and experienced a natural menopause.
2 o were premenopausal at baseline and reached natural menopause.
3 my with the changes observed up to and after natural menopause.
4 icant independent predictor of the timing of natural menopause.
5 teristics were associated with the timing of natural menopause.
6 /ethnicity were associated with later age at natural menopause.
7 sed to assess factors associated with age at natural menopause.
8 reported increased mortality risk with early natural menopause.
9 ) was associated with higher risk of earlier natural menopause.
10 e the associations between PFAS and incident natural menopause.
11 ith shorter LTL, especially among women with natural menopause.
12 ause period exhibited higher risk of earlier natural menopause.
13 can be challenging, and more severe than at natural menopause.
14 enetically predicted LTL with earlier age at natural menopause.
15 causal relationships between LTL and age at natural menopause.
16 lescent to midlife weight change with age at natural menopause.
17 e at menopause than women who have undergone natural menopause; 2) reliability declines with time sin
20 Survey (NHANES) to describe trends in age at natural menopause, age at menarche, and reproductive lif
21 herefore, we aimed to evaluate risk of early natural menopause among 107,817 members of the Nurses' H
22 vestigated factors influencing the timing of natural menopause among 95,704 women with a mean age of
23 perfluorohexane sulfonate (PFHxS) and age at natural menopause among women 20-65 years of age in NHAN
24 used to examine the relation between age at natural menopause and all-cause and cause-specific morta
25 1.36, 95% CI 1.15-1.61; P = 0.0003); age at natural menopause and endometrioid carcinoma (OR per yea
26 sk associated with MHT in women experiencing natural menopause and for late age at natural menopause
27 ed to assess the associations between age at natural menopause and incidence and timing of cardiovasc
29 in those observational studies had undergone natural menopause and were treated for the relief of men
31 with age, duration of breastfeeding, age at natural menopause, and duration of estrogen use differed
32 vely with early age at menarche, late age at natural menopause, and total length of ovulation span, b
34 g, assessed using normal variation in age at natural menopause (ANM) in about 200,000 women of Europe
40 stimate hazard ratios (HRs) for the onset of natural menopause as a function of age and serum PFC lev
41 nts previously associated with normal age at natural menopause as a quantitative trait (QT) were also
42 abortion; 1.32 (1.15, 1.51) (p = 0.008) for natural menopause at <47 compared to 50 years; 1.12 (1.0
43 53 (95% confidence interval: 0.58, 4.07) for natural menopause at age < or =45 years compared with >
44 sed women were 50% more likely to experience natural menopause at any given age (hazard ratio = 1.49,
47 erapy, who never smoked, and who experienced natural menopause between the ages of 40 and 54 years.
48 Body mass index is associated with age at natural menopause, but the influence of weight change re
52 ars (subtracting age at menarche from age at natural menopause), from 36.1 years among women born bet
53 ho underwent bilateral oophorectomy prior to natural menopause had a higher risk of restless legs syn
55 cell NHL (based on 67 cases) than women with natural menopause (hazard ratio = 1.51, 95% confidence i
56 risk of BCC was associated with late age at natural menopause (hazard ratio [HR] for >/= 55 years v
57 ces (PFAS) have been associated with earlier natural menopause; however, the underlying mechanisms ar
58 had reported their menopause status, age at natural menopause (if postmenopausal), and cardiovascula
60 ed survival analyses to estimate the risk of natural menopause in 4,210 DES-exposed versus 1,829 unex
61 ts support the hypothesis that the timing of natural menopause is driven by a combination of genetic,
62 on and Mendelian randomization, older age at natural menopause is related to lower concentrations of
65 ne withdrawal (such as following surgical or natural menopause) may impact the efficacy of progestero
67 versely associated with XFG/XFGS compared to natural menopause (MVHR = 0.37; 95% CI: 0.15, 0.92; FDR-
68 ardiovascular disease (CVD) before and after natural menopause (NM), hysterectomy with at least 1 ova
69 seven traits related to reproductive (age at natural menopause, number of children, age at first chil
72 eline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression
75 or women who experienced premature or early natural menopause should be considered for hormonal trea
76 ing association between parity and timing of natural menopause, surgical menopause, and premenopausal
77 ciation between early-life events and age at natural menopause, the authors used Cox proportional haz
79 ere fitted to examine the relation of age at natural menopause to lifestyle and anthropometric factor
81 ffect of women's lifestyles on the timing of natural menopause using data from a cross-sectional ques
86 The Kaplan-Meier estimate for median age of natural menopause was earlier in women residing in neigh
87 demographic and lifestyle factors to age at natural menopause was examined in seven US centers and f
91 ed with rate of hysterectomy, and time since natural menopause was positively associated with serum P
93 rospective cohort study of 6040 women with a natural menopause were followed up at 3-y intervals over
94 re all independently associated with earlier natural menopause, while parity, prior use of oral contr
95 isk was most increased among women reporting natural menopause who used MHT for 10 or more years vers
96 d 50,678 women (21,511 who had experienced a natural menopause) who were 40-98 years of age at study
97 n between age at menarche, parity and age at natural menopause with 249 metabolic traits in over 65,0
98 her PFAS concentrations had shorter times to natural menopause, with a relative survival of 0.82 (95%